|1.||Szala, Stanisław: 3 articles (01/2012 - 01/2006)|
|2.||Jarosz, Magdalena: 3 articles (01/2012 - 01/2006)|
|3.||Jazowiecka-Rakus, Joanna: 3 articles (01/2012 - 01/2006)|
|4.||Tai, Ming-Hong: 3 articles (01/2009 - 01/2005)|
|5.||Tosato, Giovanna: 3 articles (01/2007 - 01/2002)|
|6.||Sochanik, Aleksander: 2 articles (01/2012 - 01/2007)|
|7.||Sheu, Shwu-Jiuan: 2 articles (01/2009 - 12/2005)|
|8.||Lin, Hsiu-Chen: 2 articles (01/2009 - 12/2005)|
|9.||Bee, Youn-Shen: 2 articles (01/2009 - 12/2005)|
|10.||Xu, Ruian: 2 articles (11/2008 - 02/2008)|
01/01/2007 - "B7H3 and vasostatin combination gene therapy was effective in combating a systemic challenge of parental H22 cells, and caused the complete regression of multiple distant tumor nodules. "
09/01/2002 - "Combination therapy with the inhibitors of angiogenesis vasostatin and IP-10 is effective in reducing the rate of tumor growth but fails to induce tumor regression, suggesting that curative treatment may require supplemental drugs targeting directly the tumor cells."
10/01/2013 - "The functional domain within amino acid residues 120-180 of vasostatin (VAS) has been confirmed to be effective in inhibiting the proliferation, migration, and invasiveness of cancer cells by its suppressive capacity against angiogenesis. "
01/01/2007 - "Subcutaneous H22 tumors established in BALB/c mice were completely eradicated in response to intratumoral injection of B7H3-expressing plasmids followed 24h later by vasostatin-expressing plasmids. "
01/01/2014 - "cruzi CRT (TcCRT) better executes the antiangiogenic and anti-tumor effects of mammal CRT and its N-terminus vasostatin. "
|2.||Melanoma (Melanoma, Malignant)
01/01/2006 - "In our study, using B16(F10) murine melanoma model and electroporation we attempted intramuscular transfer of human vasostatin gene. "
01/01/2007 - "In the model of B16-F10 melanoma the MBP/vasostatin construct significantly delayed tumor growth and prolonged survival of treated mice. "
01/01/2006 - "The combination of vasostatin gene therapy and cyclophosphamide administration improved therapeutic effects in melanoma tumours. "
01/01/2006 - "Combination of vasostatin gene therapy with cyclophosphamide inhibits growth of B16(F10) melanoma tumours."
01/01/2012 - "In this study we aimed at developing an optimized scheme of administering a combination of an angiogenesis-inhibiting drug (vasostatin) and a chemotherapeutic (cyclophosphamide) in the therapeutic treatment of mice bearing experimental B16-F10 melanoma tumors. "
12/01/2005 - "The purpose of this study was to evaluate the efficacy of gene delivery of angiogenesis inhibitor, vasostatin (VS), in suppressing experimental model of choroidal neovascularization (CNV). "
01/01/2009 - "Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin."
12/01/2005 - "Suppression of choroidal neovascularization by intramuscular polymer-based gene delivery of vasostatin."
|4.||Hepatocellular Carcinoma (Hepatoma)
01/01/2007 - "The aim of this study was to determine whether vasostatin, a potent anti-angiogenic agent, could synergize with B7H3-mediated immunotherapy to combat hepatocellular carcinoma (HCC). "
01/01/2007 - "Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy."
10/01/2014 - "Plasmid-encoding vasostatin inhibited the growth and metastasis of human hepatocellular carcinoma cells."
10/01/2014 - "In this study, we attempted to investigate whether plasmid-encoding vasostatin complexed with cationic liposome could suppress the growth and metastasis of hepatocellular carcinoma in vivo and discover its possible mechanism of action. "
|5.||Neuroendocrine Tumors (Neuroendocrine Tumor)
01/01/2005 - "Therefore, one should be very careful when using vasostatin as an anti-tumoral agent in clinical trials, at least for neuroendocrine tumors."
01/01/2005 - "The results demonstrated that vasostatin transfer caused enhanced malignant behavior of neuroendocrine tumor cell line, BON. "
11/01/2008 - "But a recent report that vasostatin can enhance the malignant behavior of neuroendocrine tumor reminds us to be cautious to develop it as an anti-tumor medicine. "
01/01/2007 - "Transfection of chicken vinculin into highly malignant neuroendocrine tumor cells, vasostatin-transformed (vaso-transformed) Bon cells which expressed low levels of vinculin protein, reversed their malignant behavior and restored expression of tumor suppressor genes. "
01/01/2005 - "Vasostatin, a fragment of calreticulin, was transfected in the BON cell line to evaluate the feasibility of using it for gene therapy in neuroendocrine tumors. "
|2.||DNA (Deoxyribonucleic Acid)
|3.||chromogranin A (344-364)
|4.||Interleukin-12 (IL 12)
|2.||Heterologous Transplantation (Xenotransplantation)